Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium

Bibliography

• Marcus DA. Duloxetine use in painful conditions. Expert Opin Pharmacother 2011;12:1333-40
   PubMed Web of Science ®Google Scholar
• Miller A, Rabe-Jablonska J. The effectiveness of antidepressants in the treatment of chronic non-cancer pain—a review. Psychiatr Pol 2005;39:21-32
   PubMedGoogle Scholar
• Atkinson JH, Patel SM, Meyer JM, Is there a therapeutic window with some antidepressants for analgesic response? Curr Pain Headache Rep 2009;13:93-9
   PubMed Web of Science ®Google Scholar
• Senna ER, De Barros AL, Silva EO, Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. J Rheumatol 2004;31:594-7
   PubMed Web of Science ®Google Scholar
• Lawrence RC, Fleson DT, Helmick CG, Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58:26-35
   PubMed Web of Science ®Google Scholar
• McNally JD, Matheson DA, Bakowsky VS. The epidemiology of self-reported fibromyalgia in Canada. Chronic Dis Can 2006;27:9-16
   PubMedGoogle Scholar
• Branco JC, Bannwarth B, Failde I, Prevalence of fibromyalgia: a survey of five European countries. Semin Arthritis Rheum 2010;39:448-53
   PubMed Web of Science ®Google Scholar
• Wolfe F, Clauw DJ, Fitzcharles MA, Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 2011;38:1113-22
   PubMed Web of Science ®Google Scholar
• Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004;292:2388-95
   PubMed Web of Science ®Google Scholar
• Bellato E, Marini E, Castoldi F, Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment. Pain Res Treat 2012;2012:426130
   PubMedGoogle Scholar
• McBeth J, Mulvey MR. Fibromyalgia: mechanisms and potential impact of the ACR 2010 classification criteria. Nat Rev Rheumatol 2012;8:108-16
   PubMed Web of Science ®Google Scholar
• Gracely RH, Petzke F, Wolf JM, Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002;46:1333-43
   PubMed Web of Science ®Google Scholar
• Lee YH, Choi SJ, Ji JD, Candidate gene studies of fibromyalgia: a systematic review and meta-analysis. Rheumatol Int 2012;32:417-26
   PubMed Web of Science ®Google Scholar
• Marks DM, Shah MJ, Patkar AA, Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise. Curr Neuropharmacol 2009;7:331-6
   PubMed Web of Science ®Google Scholar
• Staud R. Pharmacological treatment of fibromyalgia syndrome: new developments. Drugs 2010;70:1-14
   PubMed Web of Science ®Google Scholar
• Goldenberg DL. Update on the treatment of fibromyalgia. Bull Rheum Dis 2004;53:1-7
   Google Scholar
• Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia: a meta-analysis and review. Psychosomatics 2000;41:104-13
   PubMed Web of Science ®Google Scholar
• O'Malley PG, Balden E, Tomkins G, Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med 2000;15:659-66
   PubMed Web of Science ®Google Scholar
• Acikalin A, Satar S, Avc A, Qtc intervals in drug poisoning patients with tricyclic antidepressants and selective serotonin reuptake inhibitors. Am J Ther 2010;17:30-3
   PubMed Web of Science ®Google Scholar
• American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616-31
   PubMed Web of Science ®Google Scholar
• Anderberg UM, Marteinsdottir I, von-Knorring L. Citalopram in patients with fibromyalgia: a randomized, double blind, placebo-controlled study. Eur J Pain 2000;4:27-35
   PubMed Web of Science ®Google Scholar
• Ozerbil O, Okundan N, Gokbel H, Comparison of the effects of two antidepressants on exercise performance of the female patients with fibromyalgia. Clin Rheumatol 2006;25:495-7
   PubMed Web of Science ®Google Scholar
• Mico JA, Ardid D, Berrocoso E, Antidepressants and pain. Trends Pharmacol Sci 2006;27:348-54
   PubMed Web of Science ®Google Scholar
• Evren B, Evren C, Guler MH. An open clinical trial of venlafaxine in the treatment of pain, depressive and anxiety symptoms in fibromyalgia. Pain Clin 2006;18:167-73
   Web of Science ®Google Scholar
• Dwight MM, Arnold LM, O'Brien H, An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 1998;39:14-17
   PubMed Web of Science ®Google Scholar
• Sayer K, Aksu G, Ak I, Venlafaxine treatment of fibromyalgia. Ann Pharmacother 2003;37:1561-5
   PubMed Web of Science ®Google Scholar
• Zijlstra TR, Barendregt EJ, van de Laar MA. Venlafaxine in fibromyalgia: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 2002;46:S105
   Google Scholar
• Pae CU, Park MH, Marks DM, Desvenlafaxine, a serotonin- norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. Curr Opin Investig Drugs 2009;10:75-90
   PubMedGoogle Scholar
• Pae CU, Marks DM, Shah M, Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol 2009;32:355-63
   PubMed Web of Science ®Google Scholar
• Arnold LM, Goldenberg DL, Stanford SB, Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007;56:1336-44
   PubMed Web of Science ®Google Scholar
• Smith HS, Barkin RL. Fibromyalgia syndrome: a discussion of the syndrome and pharmacotherapy. Am J Ther 2010;17:418-39
   PubMed Web of Science ®Google Scholar
• Alp R, Citil M, Uzun M, Effects of therapeutic doses of pregabalin on QTc interval in conscious rabbits. Eur Rev Pharmacol Sci 2008;12:223-8
   Google Scholar
• Spencer C, Wilde M. Milnacipran: a review of its use in depression. Drugs 1998;56:405-27
   PubMed Web of Science ®Google Scholar
• Forest Pharmaceuticals, Inc. Savella (milnacipran HCl) tablets: US prescribing information [online]. Available from: http://www.frx.com/pi/Savella_pi.pdf [Accessed January 2013]
   Google Scholar
• Chwieduk CM, McCormack PL. Milnacipran: in fibromyalgia. Drugs 2010;70:99-108
   PubMed Web of Science ®Google Scholar
• Vaishnavi SN, Nemeroff CB, Plott Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004;55:320-2
   PubMed Web of Science ®Google Scholar
• Moret C, Briley M. Effects of milnacipran and pindolol on extracellular noradrenaline and serotonin levels in guinea pig hypothalamus. J Neurochem 1997;69:815-22
   PubMed Web of Science ®Google Scholar
• Kitaichi Y, Inoue T, Izumi T, Effect of co-administration of a serotonin-noradrenaline reuptake inhibitor and a dopamine agonist on extracellular monoamine concentrations in rat. Eur J Pharmacol 2008;584:285-90
   PubMed Web of Science ®Google Scholar
• Mochizuki D, Tsujita R, Yamada S, Neurochemical and behavioral characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats. Psychopharmacology (Berl) 2002;162:323-32
   PubMed Web of Science ®Google Scholar
• Koch S, Hemrick-Luecke SK, Thompson LK, Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 2003;45:935-44
   PubMed Web of Science ®Google Scholar
• Mongeau R, Weiss M, de Montigny C, Effect of acute, short-and long-term milnacipran on rat locus coeruleus noradrenergic and dorsal raphe serotonergic neurons. Neuropharmacology 1998;37:905-18
   PubMed Web of Science ®Google Scholar
• Obata H, Saito S, Koizuka S, The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenalin reuptake inhibitor, in a rat model of neuropathic pain. Anesth Analg 2005;100:1406-10
   PubMed Web of Science ®Google Scholar
• Ohnami S, Kato A, Shinohara S, Effects of milnacipran, a 5-HT and noradrenaline reuptake inhibitor, on C-fibre-evoked field potentials in spinal long-term potentiation and neuropathic pain. Br J Pharmacol 2012;166:537-47
   Google Scholar
• Onal A, Parlar A, Ulker S. Milnacipran attenuates hyperalgesia and potentiates antihyperalgesic effect of tramadol in rats with mononeurpathic pain. Pharmacol Biochem Behav 2007;88:171-8
   PubMed Web of Science ®Google Scholar
• Song Z, Meyerson BA, Linderoth B. The interaction between antidepressant drugs and the pain-relieving effect of spinal cord stimulation in a rat model of neuropathy. Anesth Analg 2011;113:1260-5
   PubMed Web of Science ®Google Scholar
• Nishiyori M, Uchida H, Nagai J, Permanent relief from intermittent cold stress-induced fibromyalgia-like abnormal pain by repeated intrathecal administration of antidepressants. Mol Pain 2011;7:69
   PubMed Web of Science ®Google Scholar
• Meyerson K, Meyerson H, Meyerson N, An increase in spinal cord noradrenaline is a major contributor to the antihyperalgesic effect of antidepressants after peripheral nerve injury in the rat. Pain 2012;153:990-7
   PubMed Web of Science ®Google Scholar
• Rao SG, Trzaska ZJ, Kranzler JD, Milnacipran enhances performance in the Morris water maze in BALB/C, an inbred mouse model of anxiety. Psychiatry 2003;53:S80
   Google Scholar
• Matsumoto M, Tachibana K, Togashi H, Chronic treatment with milnacipran reverses the impairment of synaptic plasticity induced by conditioned fear stress. Psychopharmacology (Berl) 2005;179:606-12
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Rigney U, Stanley N, Pharmacodynamics of milnacipran in young and elderly volunteers. Br J Clin Pharmacol 2000;49:118-25
   PubMed Web of Science ®Google Scholar
• Poirier MF, Galinowski A, Amado I, Double-blind comparative study of the action of repeated administration of milnacipran versus placebo on cognitive functions in healthy volunteers. Hum Psychopharmacol 2004;19:1-7
   PubMed Web of Science ®Google Scholar
• Caron J, Libersa C, Hazard JR, Acute electrophysiological effects of intravenous milnacipran, a new antidepressant agent. Eur Neuropsychopharmacol 1993;3:493-500
   PubMedGoogle Scholar
• Forman MB, Sutej PG, Jackson EK. Hypertension, tachycardia and reversible cardiomyopathy temporally associated with milnacipran use. Tex Heart Inst J 2011;38:714-18
   PubMed Web of Science ®Google Scholar
• Arnold LM, Palmer RH, Hufford MR, Milnacipran's effect on body weight by baseline BMI: results across 3 randomized, double-blind, placebo-controlled fibromyalgia trials. Arthritis Rheum 2009;60(10 Suppl):1422
   Google Scholar
• Puozzo C, Filaquier C, Briley M. Plasma levels of F 2207, midalcipran, a novel antidepressant, after single oral administration in volunteer. Br J Clin Pharmacol 1985;20:291P
   Web of Science ®Google Scholar
• Puozzo C, Leonard BE. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 1996;11(Suppl 4):15-27
   PubMed Web of Science ®Google Scholar
• Vitton O, Gendreau M, Gendreau J, A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004;19(Suppl 1):S27-35
   PubMed Web of Science ®Google Scholar
• Gendreau RM, Thorn MD, Gendreau JF, Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32:1975-85
   PubMed Web of Science ®Google Scholar
• Clauw DJ, Mease P, Palmer RH, Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1998-2004
   Web of Science ®Google Scholar
• Mease PJ, Clauw DJ, Gendreau RM, The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009;36:398-409
   PubMed Web of Science ®Google Scholar
• Arnold LM, Gendreau RM, Palmer RH, Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia. Arthritis Rheum 2010;62:2745-56
   PubMed Web of Science ®Google Scholar
• Branco JC, Zachrisson O, Perrot S, A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol 2010;37:851-9
   PubMed Web of Science ®Google Scholar
• Buskila D, Cohen H. Comorbidity of fibromyalgia and psychiatric disorders. Curr Pain Headache Rep 2007;11:333-8
   PubMedGoogle Scholar
• Bennett RM, Russell J, Cappelleri JC, Identification of symptom and functional domains that fibromyalgia patients would like to see improved: a cluster analysis. BMC Musculoskelet Disord 2010;11:134
   PubMed Web of Science ®Google Scholar
• Goldenberg DL, Clauw DJ, Palmer RH, Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med 2010;11:180-94
   PubMed Web of Science ®Google Scholar
• Ferrera R, Palmer R, Chen W, Improvements in fibromyalgia symptoms are sustained for 1 year with milnacipran treatment: results from 2 double-blind, dose-controlled extension studies [abstract]. J Pain 2009;10(4 Suppl 1):S60
   PubMed Web of Science ®Google Scholar
• Branco JC, Cherin P, Montagne A, Long-term therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study. J Rheumatol 2011;38:1403-12
   PubMed Web of Science ®Google Scholar
• Arnold L, Spera A, Baldecchi A, A three-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia. J Pain 2011;12(4 Suppl 2):S22
   PubMed Web of Science ®Google Scholar
• Hauser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain 2010;11:505-21
   PubMed Web of Science ®Google Scholar
• Mease PJ, Zimetbaum PJ, Duh MS, Epidemiologic evaluation of cardiovascular risk in patients receiving milnacipran, venlafaxine, or amitriptyline: evidence of French health data. Ann Pharmacother 2011;49:177-88
   Google Scholar
• Ursini F, Naty S, Grembiale RD. Fibromyalgia and obesity: the hidden link. Rheumatol Int 2011;31:1403-8
   PubMed Web of Science ®Google Scholar
• Arnold LM, Palmer RH, Hufford MR, Effect of milnacipran on body weight in patients with fibromyalgia. Int J Gen Med 2012;5:879-87
   PubMedGoogle Scholar
• Hauser W, Wolfe F, Tolle T, The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs 2012;26:297-307
   PubMed Web of Science ®Google Scholar
• Smith MT, Mo ore BJ. Pregabalin for the treatment of fibromyalgia. Expert Opin Pharmacother 2012;13:1527-33
   PubMed Web of Science ®Google Scholar
• Nuesch E, Hauser W, Bernardy K, Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis 2012; In press
   PubMed Web of Science ®Google Scholar
• Han C, Lee SJ, Lee SY, Available therapies and current management of fibromyalgia: focusing on pharmacological agents. Drugs Today 2011;47:539-57
   PubMed Web of Science ®Google Scholar
• Bennett RM, Jones J, Turk DC, An internet survey of 2596 people with fibromyalgia. BMC Musculoskel Disorders 2007;9:27-38
   Web of Science ®Google Scholar
• Farmer MV, Palmer RH, Wang Y, Efficacy of milnacipran when added to pregabalin in the management of fibromyalgia: a randomized, open-label, controlled study. Ann Rheum Dis 2010;69:448
   Google Scholar
• Okifuji A, Bradshaw DH, Olson C. Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms and functions. Clin Rheumatol 2009;28:475-8
   PubMed Web of Science ®Google Scholar
• Smith B, Peterson K, Fu R, Drug Class Review: Drugs for Fibromyalgia: Final original report. Oregon Health & Sciences University. 2011. Available from: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0010224/ [Accessed January 2013]
   Google Scholar
• Arnold LM, Crofford LJ, Mease PJ, Patient perspectives on the impact of fibromyalgia. Patient Educ Couns 2008;73:114-20
   PubMed Web of Science ®Google Scholar
• Barbehenn E, Wolfe S. Petition to ban fibromyalgia drug milnacipran (Savella). 2010. Available from: http://www.citizen.org/Page.aspx?pid=2596 [Accessed January 2010]
   Google Scholar